Eli Lilly and Company (NYSE: LLY) today announced the details of presentations at the European Hematology Association (EHA) ...

Cash position -- $15 million in cash and cash equivalents as of March 31, 2026, with potential for up to $20.2 million in additional gross proceeds upon exercise of PIPE Series B warrants, triggered ...

Eli Lilly LLY announced that the phase III BRUIN CLL-313 study, evaluating its BTK inhibitor Jaypirca (pirtobrutinib) versus chemoimmunotherapy (bendamustine plus rituximab) in treatment-naïve ...

Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and suppress normal blood cell formation. These particles affected monocytes, ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of ...

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

Komodo Health claims analyses in first-line CLL showed zanubrutinib associated with lower mortality (adjusted HR 0.75) and improved TTNT (HR 0.89) versus acalabrutinib. In R/R MCL (≥2L), zanubrutinib ...

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...

Progress against cancer doesn’t always arrive as headlines. Often, it shows up quietly in longer lives, better tolerability, ...

The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy. People with CLL have a higher risk of developing skin cancers, including SCC, explained ...